Look behind the lecture: knowing what data are best suited to answer a question – an interview with Anja Schiel

Written by Anja Schiel (Norwegian Medicines Agency)

In this feature, following moderating a Spotlight session at the International Society for Pharmacoeconomics and Outcomes Research’s 2020 Europe meeting (Virtual ISPOR Europe 2020; 16–19 November), Anja Schiel (Norwegian Medicines Agency; NoMA, Oslo, Norway) shares her insight on the European regulatory perspective on the usability and credibility of real-world data and evidence (RWD/E). Please can you introduce yourself and your organization? I work at the NoMA as a Statistician/Methodologist: my work is mainly focused on translating statistical and methodological issues in trial designs into a clinical description of the problem. In essence, I help my clinical and health economics colleagues...

To view this content, please register now for access

It's completely free